Latest Intellectual Property News

Li-S Energy has secured a strategic defence collaboration, advanced its Pegasus I drone testing, and commissioned Australia's first lithium metal foil production line, all while maintaining a solid cash position.

Neometals has reported a maiden Mineral Resource Estimate for its Ironclad gold deposit at Barrambie and signed a non-binding MoU with Rio Tinto to advance its lithium processing technology, alongside progress in battery recycling plant commissioning.

PentaNet Ltd reported positive operating cash flow for the June 2025 quarter and strengthened its financial position with a new $2 million equipment finance facility.

Emyria has secured a landmark multi-year funding agreement with Medibank to reimburse PTSD patients under its Empax program, alongside opening a second clinic and reporting durable clinical improvements in treatment-resistant PTSD cases.

PlaySide Studios has raised $6.6 million through a share placement to bolster its balance sheet ahead of the launch of its new original game, MOUSE, P.I. For Hire. The capital raise includes director participation and an upcoming Share Purchase Plan for existing shareholders.

IMDEX has acquired an 80.5% stake in Norway’s Earth Science Analytics for A$26 million, integrating its AI-driven EarthNET platform to boost digital orebody knowledge across mining and energy sectors.

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.

Patrys Limited has announced a fully underwritten entitlement offer to raise approximately $1.77 million, aimed at funding ongoing research and development of its PAT-DX3 therapy and supporting working capital. The offer includes secondary options and shares, subject to shareholder approval, and will significantly expand the company's capital base.

Patrys Limited has launched a fully underwritten entitlement offer to raise approximately $1.77 million, aiming to accelerate development and commercial activities around its deoxymabs program.

Argenica Therapeutics has dosed the final patient in its Phase 2 trial for ARG-007 in acute ischaemic stroke, with topline results expected in Q3 2025. Meanwhile, the FDA has placed a clinical hold on its US trial application, introducing uncertainty for US development.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.